ATEC Equipped to Support Ramping Surgical Volume With Proceeds From Secondary Offering
- None.
- None.
Positioned to invest in revenue-generating assets as Company continues to capitalize on industry disruptions
“We would like to thank our existing and new shareholders for their confidence as we better position ATEC for long-term growth by exploiting unprecedented industry turmoil,” said Pat Miles, Chairman and Chief Executive Officer. “The pandemic taught us an important lesson: when peers are disrupted, it is the ideal time for thoughtful, bold actions that drive sustained market share expansion.”
Miles added, “ATEC clinical distinction continues to attract surgeons and sales talent, and the momentum of that interest has escalated significantly. We have begun to address the roughly one-third of
Third Quarter 2023 Select Preliminary Financial Results
The Company continues to expect the following:
-
Third quarter 2023 total revenue of
to$117.7 million , implying total revenue growth of 31 to$118.5 million 32% ; -
Third quarter 2023 adjusted EBITDA of
to$1.5 million ;$2.3 million -
Full-year 2023 total revenue of approximately
.$472 million
ATEC expects to announce third quarter 2023 financial and operating results on November 6, 2023, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET.
Webcast
To access the live webcast, please visit the Investor Relations Section of ATEC’s Corporate Website.
Dial-in
To dial into the live webcast, please register at this link. Access details will be shared via email.
Replay
A replay of the webcast will remain available through the Investor Relations Section of ATEC’s Corporate Website for twelve months. In addition, a dial-in replay will be available through November 13, 2023. Access the replay by dialing (800) 770-2030 and referencing conference ID number 97241.
Non-GAAP Financial Information
To supplement the Company’s financial statements presented in accordance with generally accepted accounting principles in
Third Quarter Ended September 30, 2023 (Unaudited, in millions) |
|||||||
Net loss |
$ |
(43.2 |
) |
to |
$ |
(42.4 |
) |
Interest and other expense |
|
4.4 |
|
to |
|
4.4 |
|
Income tax provision (benefit) |
|
(0.1 |
) |
to |
|
(0.1 |
) |
Depreciation |
|
10.6 |
|
to |
|
10.6 |
|
Amortization of intangibles |
|
4.1 |
|
to |
|
4.1 |
|
|
|||||||
EBITDA |
|
(24.2 |
) |
to |
|
(23.4 |
) |
|
|||||||
Add back significant items: |
|
||||||
Stock-based compensation |
|
20.1 |
|
to |
|
20.1 |
|
Excess and obsolete charges |
|
2.5 |
|
to |
|
2.5 |
|
Litigation-related expenses |
|
2.7 |
|
to |
|
2.7 |
|
Transaction-related expenses |
|
0.3 |
|
to |
|
0.3 |
|
Restructuring expenses |
|
0.1 |
|
to |
|
0.1 |
|
|
|||||||
Adjusted EBITDA |
$ |
1.5 |
|
to |
$ |
2.3 |
|
About ATEC
ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation Machine™ is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to be the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described therein. Forward-looking statements include references to the Company’s expectations with respect to future revenue and growth. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: failure to achieve acceptance of the Company’s products by the surgeon community and changes to our financial results for the quarter ended September 30, 2023 due to the completion of financial closing procedures. The words “believe,” “will,” “should,” “expect,” “intend,” “estimate,” “look forward” and “anticipate,” and variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231031080616/en/
Investor/Media Contact:
Tina Jacobsen, CFA
Investor Relations
(760) 494-6790
investorrelations@atecspine.com
Company Contact:
J. Todd Koning
Chief Financial Officer
Alphatec Holdings, Inc.
investorrelations@atecspine.com
Source: Alphatec Holdings, Inc.
FAQ
What is the recent news from Alphatec Holdings, Inc.?
What does the secondary offering position the company to do?
What are the expected third quarter 2023 total revenue growth and full-year 2023 total revenue?